Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
Johnson & Johnson
Advertisement
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Johnson & Johnson Wins EU Approval for ICOTYDE in Psoriasis
Beerse, Belgium, September 21, 2026 Johnson & Johnson has reached a major European regulatory milestone with the European Commission’s...
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Mania Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Johnson & Johnson TECVAYLI Gains Positive CHMP Opinion
Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...
Advertisements
Nanobiotix Advances JNJ-1900 in Recurrent NSCLC
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
Johnson & Johnson Highlights New Neuropsychiatry Data
Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...
Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Johnson & Johnson Launches Global DISH Surgical Outcomes System
August 24, 2026 | New Brunswick, New Jersey Johnson & Johnson announced the publication of the DISH Classification System,...
Advertisement
